Get the Stockscreener App
22.37
1.45%
-0.33
After Hours:
22.37
Acadia Pharmaceuticals Inc stock is traded at $22.37, with a volume of 1.82M.
It is down -1.45% in the last 24 hours and up +2.61% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$22.70
Open:
$22.5
24h Volume:
1.82M
Relative Volume:
0.88
Market Cap:
$3.77B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
124.28
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
-2.70%
1M Performance:
+2.61%
6M Performance:
+50.03%
1Y Performance:
+51.05%
1-Day Range:
$21.87
$22.78
1-Week Range:
$21.87
$23.05
52-Week Range:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.37 | 3.83B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Citigroup | Buy |
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
ACADIA Pharmaceuticals board member Daniel Soland resigns - StreetInsider
[8-K] ACADIA PHARMACEUTICALS INC Reports Material Event | ACAD SEC FilingForm 8-K - Stock Titan
How ACADIA Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Understanding ACADIA Pharmaceuticals Inc.’s price movementFed Meeting & Real-Time Buy Signal Alerts - newser.com
Is ACADIA Pharmaceuticals Inc. stock trading near support levelsWeekly Trade Summary & Low Risk Growth Stock Ideas - newser.com
Price momentum metrics for ACADIA Pharmaceuticals Inc. explainedWeekly Risk Report & High Conviction Trade Alerts - newser.com
Will ACADIA Pharmaceuticals Inc. stock split again soonJuly 2025 Volume & Daily Stock Trend Watchlist - newser.com
Why ACADIA Pharmaceuticals Inc. stock remains undervaluedMarket Trend Summary & High Conviction Buy Zone Alerts - newser.com
Is ACADIA Pharmaceuticals Inc. stock a top momentum playJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - newser.com
ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Reactions & AI Powered Market Entry Ideas - newser.com
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo! Finance UK
Why ACADIA Pharmaceuticals Inc. stock is rated strong buyRisk Management & Weekly Setup with ROI Potential - newser.com
ACADIA Pharmaceuticals Inc. (ACAD) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
EBITDA per share of ACADIA Pharmaceuticals Inc. – DUS:DR6 - TradingView
Is ACADIA Pharmaceuticals Inc. reversing from oversold territoryJuly 2025 Action & Weekly High Potential Alerts - newser.com
What drives ACADIA Pharmaceuticals Inc stock priceStock Buyback Announcements & Fast Growing Trading Plans - earlytimes.in
Ranking ACADIA Pharmaceuticals Inc. among high performing stocks via toolsQuarterly Trade Report & Daily Market Momentum Tracking - newser.com
ACADIA Pharmaceuticals Surges 53% as New Product Launches Fuel Fresh Valuation Debate - Sahm
ACADIA Pharmaceuticals Advances Phase 3 Study for Lewy Body Dementia Psychosis Treatment - MSN
Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekersMarket Activity Summary & Safe Entry Point Alerts - newser.com
How ACADIA Pharmaceuticals Inc. stock performs after earningsJuly 2025 Weekly Recap & Community Supported Trade Ideas - newser.com
Emerald Mutual Fund Advisers Trust Sells 175,778 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
How sentiment analysis helps forecast ACADIA Pharmaceuticals Inc.2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com
Is ACADIA Pharmaceuticals Inc. stock supported by strong fundamentalsTrend Reversal & Stepwise Swing Trade Plans - newser.com
Real time alert setup for ACADIA Pharmaceuticals Inc. performanceJuly 2025 Sector Moves & Consistent Profit Trade Alerts - newser.com
Acadia Pharma plots space to grow at Kilroy's big South San Francisco campus - The Business Journals
ACADIA Pharmaceuticals (ACAD): Exploring Valuation as Investor Interest Rises on Pipeline Momentum - Yahoo Finance
Emerald Advisers LLC Sells 223,547 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Advances Study on Carbetocin Nasal Spray for Prader-Willi Syndrome - MSN
ACADIA’s ACP-204 Study: A Promising Step for Alzheimer’s Disease Psychosis Treatment - MSN
12,050 Shares in ACADIA Pharmaceuticals Inc. $ACAD Bought by Yorktown Management & Research Co Inc - MarketBeat
ACADIA Pharmaceuticals (ACAD): Exploring Valuation After Strong Share Price Momentum and Pipeline Progress - Sahm
ACADIA Pharmaceuticals (ACAD) to Release Quarterly Earnings on Wednesday - MarketBeat
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):